Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Changes To UK Price Scheme To Hit Profits, Biosimilar Launches

Proposed changes to the UK statutory scheme for controlling the costs of branded medicines bought by the National Health Service would hit company profits and could deter biosimilar launches.

Europe United Kingdom

European Commission Responds To French Concerns On Joint HTA Cooperation Proposals

The European Commission continues to try and ease concerns EU member states have over its proposals to drive cooperation on health technology assessments and the mandatory use of joint clinical assessment reports.


BioPharmaceutical Comparative Effectiveness

Colombian Pharma Industry Raises Concerns Over Pricing Proposals

A draft circular on pricing has raised the spectre of price controls being applied with little warning for companies, the Colombian research-based pharmaceutical industry has warned.

South America Colombia

Cross Country Coalitions Must ‘Guarantee Confidential Pricing And Improve Access’

Industry says that if cross country-coalitions on pricing and reimbursement are to succeed, the member countries need to be similar in terms of GDP and to guarantee pricing is kept confidential.

Europe Belgium

Vertex Rejects England’s Orkambi Offer

Vertex has rejected the “final offer” put forward by the National Health Service in England for its cystic fibrosis drugs, including Orkambi. The company’s chief executive wants a meeting with the head of the NHS.

United Kingdom Reimbursement

Biogen: BeNeLuxA Spinraza Talks “Collaborative And Constructive" But Not Without Challenges

Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.

Europe Belgium
See All